A Phase 2 interventional study of BAY2433334 and Apixaban in Atrial Fibrillation (AF), sponsored by Bayer. Completed at 93 sites in 14 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-10-27.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.
Among the 64 studies in Atrial Fibrillation by Bayer, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2020, is one of 6 in phase 2, and was the 56th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 100 across the 13 interventional studies, 3,055 across the 51 observational. Of the 61 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 64 studies in Atrial Fibrillation by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral anticoagulant (NOAC) in patients with atrial fibrillation. This study is also done to learn how the drug in this study moves into, through and out of the body. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Apixaban, works by reducing the production of blood clotting factors in our body and thins the blood and is a so called non-vitamin K oral anticoagulant (NOAC). Thinning the blood can prevent you from blood clots which can cause a stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with AF documented by evidence with
Indication for treatment with an oral anticoagulant in
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BAY2433334 · Other: Apixaban matching placebo
Drug: BAY2433334 · Other: Apixaban matching placebo
Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
Drug: Apixaban · Other: BAY2433334 matching placebo
Tablet, taken orally once a day.
Capsule, taken orally twice a day.
Tablet, taken orally once a day.
Capsule, taken orally twice a day.
Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.
Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Number of Participants With All Bleeding
Adjudication of all bleeding events was performed by members of the Clinical events committee (CEC) who reviewed events in a blinded fashion and adjudicated and classified the following events in a consistent and unbiased manner according to the following classifications: ISTH (major, clinically relevant non-major and minor); Thrombolysis in myocardial infarction (TIMI major, minor, requiring medical attention, minimal); Bleeding Academic Research Consortium (BARC type 1, 2, 3, 5).
Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Number of Participants With ISTH Major Bleeding
ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood.
Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding
ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.
Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Number of Participants With ISTH Minor Bleeding
All other overt bleeding episodes not meeting ISTH Major Bleeding criteria or clinically relevant non major bleeding were classified as minor bleeding.
Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Study was conducted at 94 centers in 14 countries or regions, between 30-Jan-2020 (first participant first visit) and 08-Oct-2021 (last participant last visit)
| Milestone | Asundexian 20 mg | Asundexian 50 mg | Apixaban |
|---|---|---|---|
| Started | 251 | 254 | 250 |
| Treated | 249 | 254 | 250 |
| Completed | 226 | 227 | 218 |
| Not completed | 25 | 27 | 32 |
| Withdrew: Death | 1 | 2 | 3 |
| Withdrew: Adverse event | 13 | 14 | 11 |
| Withdrew: Other | 7 | 5 | 14 |
| Withdrew: Physician decision | 1 | 3 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 |
| Withdrew: Study drug never administered | 2 | 0 | 0 |
Adjudication of all bleeding events was performed by members of the Clinical events committee (CEC) who reviewed events in a blinded fashion and adjudicated and classified the following events in a consistent and unbiased manner according to the following classifications: ISTH (major, clinically relevant non-major and minor); Thrombolysis in myocardial infarction (TIMI major, minor, requiring medical attention, minimal); Bleeding Academic Research Consortium (BARC type 1, 2, 3, 5).
| Participants | Asundexian 20 mg | Asundexian 50 mg | Asundexian Pooled | Apixaban |
|---|---|---|---|---|
| Number of Participants With All Bleeding | 12 | 10 | 22 | 26 |
ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood.
| Participants | Asundexian 20 mg | Asundexian 50 mg | Apixaban |
|---|---|---|---|
| Number of Participants With ISTH Major Bleeding | 0 | 0 | 0 |
ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.
| Participants | Asundexian 20 mg | Asundexian 50 mg | Asundexian Pooled | Apixaban |
|---|---|---|---|---|
| Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding | 3 | 1 | 4 | 6 |
All other overt bleeding episodes not meeting ISTH Major Bleeding criteria or clinically relevant non major bleeding were classified as minor bleeding.
| Participants | Asundexian 20 mg | Asundexian 50 mg | Asundexian Pooled | Apixaban |
|---|---|---|---|---|
| Number of Participants With ISTH Minor Bleeding | 10 | 9 | 19 | 20 |
ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.
| Participants | Asundexian 20 mg | Asundexian 50 mg | Asundexian Pooled | Apixaban |
|---|---|---|---|---|
| Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding | 3 | 1 | 4 | 6 |
Collected over After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration). Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, with an average of 14 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asundexian 50 mg | 4/254 (1.6%) | 20/254 (7.9%) | 116/254 (45.7%) |
| Asundexian 20 mg | 2/249 (0.8%) | 22/249 (8.8%) | 110/249 (44.2%) |
| Apixaban | 5/250 (2%) | 20/250 (8%) | 113/250 (45.2%) |
| Event | Asundexian 50 mg | Asundexian 20 mg | Apixaban |
|---|---|---|---|
| Cardiac failureCardiac disorders | 4/254 | 3/249 | 3/250 |
| Atrial fibrillationCardiac disorders | 3/254 | 3/249 | 2/250 |
| Cerebrovascular accidentNervous system disorders | 1/254 | 2/249 | 0/250 |
| PalpitationsCardiac disorders | 0/254 | 1/249 | 0/250 |
| Sinus arrestCardiac disorders | 0/254 | 1/249 | 0/250 |
| Congestive cardiomyopathyCardiac disorders | 0/254 | 1/249 | 0/250 |
| Sinus node dysfunctionCardiac disorders | 0/254 | 1/249 | 1/250 |
| Inguinal herniaGastrointestinal disorders | 0/254 | 1/249 | 0/250 |
| NauseaGastrointestinal disorders | 0/254 | 1/249 | 0/250 |
| Rectal haemorrhageGastrointestinal disorders | 0/254 | 1/249 | 0/250 |
| Event | Asundexian 50 mg | Asundexian 20 mg | Apixaban |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/254 | 3/249 | 11/250 |
| DiarrhoeaGastrointestinal disorders | 11/254 | 4/249 | 5/250 |
| FatigueGeneral disorders | 10/254 | 5/249 | 2/250 |
| DizzinessNervous system disorders | 8/254 | 9/249 | 7/250 |
| NauseaGastrointestinal disorders | 8/254 | 6/249 | 9/250 |
| Atrial fibrillationCardiac disorders | 8/254 | 7/249 | 7/250 |
| HypertensionVascular disorders | 5/254 | 6/249 | 7/250 |
| HeadacheNervous system disorders | 7/254 | 4/249 | 5/250 |
| Abdominal pain upperGastrointestinal disorders | 3/254 | 2/249 | 6/250 |
| HaematuriaRenal and urinary disorders | 0/254 | 2/249 | 6/250 |
SAF (safety analysis set)
| Age, Categorical(Participants) | Asundexian 20 mg | Asundexian 50 mg | Apixaban | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 43 | 34 | 110 |
| >=65 years | 216 | 211 | 216 | 643 |
| Sex: Female, Male(Participants) | Asundexian 20 mg | Asundexian 50 mg | Apixaban | Total |
|---|---|---|---|---|
| Female | 102 | 97 | 109 | 308 |
| Male | 147 | 157 | 141 | 445 |
| Race/Ethnicity, Customized(Participants) | Asundexian 20 mg | Asundexian 50 mg | Apixaban | Total |
|---|---|---|---|---|
| Asian | 39 | 40 | 40 | 119 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 209 | 212 | 209 | 630 |
| Not reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Jan 2020 to primary completion in Oct 2021, 20 months.
Results were first posted in Oct 2022, 1 year after primary completion.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asundexian